Atıf Sayısı
7
Görüntüleme
18
İndirme
9
Bu çalışmada diyabetin mikrovasküler komplikasyonlarından olan diyabetik nöropatisi olan hastalarda monosit/HDL kolesterol oranı (MHR)’nin kardiyovasküler risk belirteci olup olamayacağının araştırılması amaçlanmıştır. Dahiliye polikliniğimizdeki Ocak 2018- Eylül 2018 tarihleri arasındaki hastalardan 30 diyabetik nöropatisi (DN) olan diabetes mellitus (DM) hastası, 29 DN olmayan DM hastası ve aynı yaş ve cinsiyette 30 DM olmayan sağlıklı retrospektif olarak çalışmaya alındı. Yaş, cinsiyet, vücut kitle indeksi (BMI), sigara, DM süresi, hipertansiyon, hemogramdaki monosit sayısı, glikozile hemoglobin A1c (HbA1c), total kolesterol, düşük yoğunluklu lipoprotein LDL kolesterol (LDL-K), yüksek yoğunluklu lipoprotein HDL kolesterol (HDL-K), trigliserid (TG) ve mikroalbuminüri, MHR, Framingham Kardiyovasküler Risk Skorlamasına (FCR) göre olan kardiyovasküler risk oranı incelendi. DN ile DN-olmayan diyabetikler arasında DM süresi açısından fark olduğu görüldü (p<0.05). DN grubun total kolesterol düzeyleri DN-olmayan gruptan (p<0.05) ve kontrol grubundan (p<0.01) yüksek bulundu. Yine DN grubun HbA1c düzeyleri de daha yüksek bulundu (p<0.001). Kontrol grubunun FCR skorları DN ve DN olmayan gruptan anlamlı şekilde düşüktü (p<0001). Grupların MHR’si arasında fark bulunmadı. Tüm hastalarda MHR ile HbA1c, FCR skorları arasında korelasyon bulundu (Spearman’s rho p <0.05). Bu çalışmada diyabetik nöropatisi olan hastalarda MHR’nin kardiyovasküler risk belirteci olabileceği sonucuna ulaşılamamıştır. Ancak tüm hastalarda MHR ile kardiyovasküler risk arasında bir korelasyon görülmüştür. Bu konuda daha geniş serilerde çalışma yapılmasına ihtiyaç vardır.
The aim of this study was to investigate whether the monocyte/HDL cholesterol ratio (MHR) could be a marker of cardiovascular risk in patients with diabetic neuropathy which is one of the microvascular complication of diabetes. 30 patients with diabetic neuropathy (DN), 30 patients with non-DN- diabetes mellitus (DM), 30 healthy individuals with non-DM the same age and sex in our internal medicine clinic between January 2018 and September 2018 were retrospectively studied. Age, gender, body mass index (BMI), smoking, hypertension, the number of monocytes, HbA1c, total cholesterol, low density lipoprotein LDL-cholesterol (LDL-C), high density lipoprotein HDL-cholesterol (HDL-C), triglyceride, microalbuminuria, MHR, Framingham Cardiovascular Risk Scoring (FCR) were investigated. There was a significant difference in the duration of DM between non-DN and diabetic patients (p <0.05). Total cholesterol levels of the DN group were higher than non-DN group (p <0.05) and control group (p <0.01). The FCR scores of the control group were significantly lower than the DN and non-DN groups (p <0001).There was no difference between MHR and HbA1c and FCR scores in all patients (Spearman's rho p <0.05). In this study, we could not conclude that MHR can be a predictor of cardiovascular risk in patients with diabetic neuropathy. However, there was a correlation between cardiovascular risk and MHR in all patients. There is a need for further studies on this subject.
The aim of this study was to investigate whether monocyte/HDL cholesterol ratio (MHR) could be a marker of cardiovascular risk in patients with diabetic neuropathy which is one of the microvascular complication of diabetes. 30 patients with diabetic neuropathy (DN), 30 patients with non-DN- diabetes mellitus (DM), 30 healthy individuals with non-DM same age and sex in our internal medicine clinic between January 2018- September 2018 were retrospectively studied. Age, gender, body mass index (BMI), smoking, hypertension, the number of monocytes, HbA1c, total cholesterol, low density lipoprotein LDL-cholesterol (LDL-C), high density lipoprotein HDL-cholesterol (HDL-C), triglyceride, microalbuminuria, MHR, Framingham Cardiovascular Risk Scoring (FCR) were investigated. There was a significant difference in the duration of DM between non-DN and diabetic patients (p <0.05). Total cholesterol levels of DN group were higher than non-DN group (p <0.05) and control group (p <0.01). The FCR scores of the control group were significantly lower than the DN and non-DN groups (p <0001).There was no difference between MHR and HbA1c and FCR scores in all patients (Spearman’s rho p <0.05). In this study, we could not conclude that MHR can be a predictor of cardiovascular risk in patients with diabetic neuropathy. However, there was a correlation between cardiovascular risk and MHR in all patients. There is a need for further studies on this subject.
Dergi Türü : Uluslararası
Makale Detay 
Atıf Yapanlar
Benzer Makaleler
PDF Görüntüle
Dergi Bilgisi
Eseri Dinleyin
Bu Sayfayı Yazdırın
Paylaş
Mendeley
